AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8363067
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia followed by intravenous morphine (GA)
Trial: 3539618
Drug: Metoprolol 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 15 mg i.v. + 50 mg q.i.d. orally
Trial: 1837931
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nebulized ipratropium bromide
Trial: 1837931
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg nebulized ipratropium bromide
Trial: 1837931
Drug: Nebulized terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbutaline (5 mg) administered 2 hours after ipratropium
Trial: 22044044
Drug: Oral antioxidants
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidants (AOs) treatment with α‐lipoic acid at 400 mg/day in association with genistein and vitamins
Trial: 19387424
Drug: Atomoxetine (0.5‐1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (0.5‐1.8 mg/kg per day)
Trial: 12903414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without drugs)
Trial: 9233529
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 on day 1 and oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Trial: 9233529
Drug: Paclitaxel 160
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 160 mg/m2 on day 5 (schedule B)
Trial: 9233529
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 on day 1 with oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Trial: 1345132
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (50 units/kg IV immediately after antivenom, followed by continuous infusion of 10 units/kg/hour for 24 hours)
Trial: 3549872
Drug: Piracetam 2
RxNorm normalized name: piracetam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 2 X 3 g
Trial: 3549872
Drug: Piracetam 2
RxNorm normalized name: piracetam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 2 X 12 g
Trial: 30329199
Drug: Study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug (0.5 mg tyrothricin, 1.0 mg benzalkonium chloride, and 1.5 mg benzocaine)
Trial: 25042199
Drug: Siltuximab (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab (11 mg/kg intravenous infusion every 3 weeks)
Trial: 22397837
Drug: High-flavanol chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol chocolate containing maltitol (266 mg)
Trial: 22397837
Drug: High-flavanol chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol chocolate with sucrose (251 mg)
Trial: 22397837
Drug: Low-flavanol chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol chocolate with sucrose (48 mg)
Trial: 18245199
Drug: Atrial pacing
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON
Trial: 18245199
Drug: Atrial pacing
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF
Trial: 18245199
Drug: Atrial pacing
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON with septal lead placement
Trial: 18245199
Drug: Atrial pacing
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF with septal lead placement
Trial: 16193675
Drug: Botulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin‐A injections (20 units in one single injection)
Trial: 16193675
Drug: Botulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin‐A injections
Trial: 12956915
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of two per cent lignocaine and adrenaline 1:200000 with 1500 IU hyaluronidase
Trial: 12956915
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of two per cent lignocaine and adrenaline 1:200000
Trial: 2070654
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent 5‐fluorouracil cream
Trial: 27569737
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous ibuprofen injection (0.2g, 0.4g, 0.8g) administered as a 30-minute IV infusion.
Trial: 27569737
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of intravenous ibuprofen (0.4g every 6 hours for 9 doses).
Trial: 27569737
Drug: Tolerability assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerability assessment of intravenous ibuprofen.
Trial: 24576858
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of fast‐acting β2‐agonist (BD)
Trial: 22958874
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dextromethorphan
Trial: 20189608
Drug: Pulsatile insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile insulin infusion therapy
Trial: 18514865
Drug: Multimodal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal oral pain medication protocol including preemptive oral analgesics, epidural anesthesia, pericapsular analgesic injection, and postoperative analgesia without parenteral opioids
Trial: 18514865
Drug: Multimodal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal oral pain medication protocol
Trial: 16230877
Drug: niacin extended-release/lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin extended-release/lovastatin 1000/40 mg
Trial: 16230877
Drug: simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 10 mg and 20 mg
Trial: 8706296
Drug: Intravenous beta-endorphin
RxNorm normalized name: beta-endorphin human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous beta-endorphin 5 mg/50 ml
Trial: 1796228
Drug: Ivermectin 100
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 100 mcg/kg and DEC 3 mg/kg (twice a year)
Trial: 1796228
Drug: Microfilaricidal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfilaricidal drugs
Trial: 6849786
Drug: Solpadeine (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solpadeine (paracetamol with codeine and caffeine)
Trial: 6849786
Drug: Panadol (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panadol (paracetamol alone)
Trial: 6849786
Drug: Paramax (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paramax (paracetamol with metoclopramide)
Trial: 17638634
Drug: Bisacodyl suppository
RxNorm normalized name: bisacodyl Rectal Suppository
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bisacodyl suppository
Trial: 12173729
Drug: Miglitol 25
RxNorm normalized name: miglitol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 25 mg t.i.d.
Trial: 12173729
Drug: Miglitol 50
RxNorm normalized name: miglitol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 50 mg t.i.d.
Trial: 12173729
Drug: Miglitol 100
RxNorm normalized name: miglitol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 100 mg t.i.d.
Trial: 12173729
Drug: Miglitol 200
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol 200 mg t.i.d.
Trial: 9452226
Drug: 8-drugs-in-1-day (8-in-1)
RxNorm normalized name: goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-drugs-in-1-day (8-in-1) chemotherapy followed by radiotherapy
Trial: 9452226
Drug: 8 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 cycles of chemotherapy
Trial: 7884950
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8
Trial: 7884950
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant treatment
Trial: 192808
Drug: Intravenous adenine
RxNorm normalized name: Adenine
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenine arabinoside (ara‐A)
Trial: 30739540
Drug: Kinesiotaping (KT)
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Kinesiotaping (KT) plus routine COPD medical treatment
Trial: 30739540
Drug: Routine COPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine COPD medical treatment
Trial: 29197413
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of NOAC therapy (≤ 4 days after stroke onset)
Trial: 29197413
Drug: Delayed initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed initiation of NOAC therapy (≥ 5-10 days after stroke onset)
Trial: 23369879
Drug: 10mg amlodipine/80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg amlodipine/80mg atorvastatin (test product)
Trial: 19473629
Drug: High-dose ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ARB (losartan 200 mg/day)
Trial: 19473629
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose ARB (losartan 100 mg/day)
Trial: 19473629
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose ACEI (20 mg/day)
Trial: 19473629
Drug: Low-dose ACEI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACEI (10 mg/day)
Trial: 9519234
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 2 mg daily via metered-dose inhaler and Volumatic
Trial: 8592675
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone (NEF) infused into the proximal intestine (400 mg over 5 hours)
Trial: 8592675
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone (NEF) infused into the distal intestine (400 mg over 5 hours)
Trial: 8592675
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone (NEF) administered orally (10 divided doses over 4.5 hours)
Trial: 793781
Drug: Nethaprin Dospan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nethaprin Dospan (active drug)
Trial: 31155953
Drug: Broccoli sprout
RxNorm normalized name: BROCCOLI SPROUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprout extract (BSE) 200 µmol daily
Trial: 30385101
Drug: Narrative Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Medicine (NM) workshop
Trial: 28777758
Drug: Exenatide 2mg
RxNorm normalized name: EXENATIDE 2MG/VIL INJ SA SUSP
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide 2mg (Bydureon) administered via once-weekly subcutaneous injections for 48 weeks
Trial: 24585506
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg orally daily
Trial: 22211733
Drug: Basal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal plus 3.5 g l-Lys/kg diet (T2)
Trial: 22211733
Drug: Basal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal plus 1.5 g l-Leu/kg diet (T3)
Trial: 22211733
Drug: Basal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal plus 3.5 g l-Lys plus 1.5 g l-Leu/kg diet (T4)
Trial: 19957624
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine from lot 1
Trial: 19957624
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine from lot 2
Trial: 19957624
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine from lot 3
Trial: 19957624
Drug: Licensed control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed control vaccine
Trial: 31112203
Drug: Unmodified α‐1,3‐glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified α‐1,3‐glucan solution
Trial: 28716797
Drug: Regular low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regular low-dose extended-release morphine
Trial: 28716797
Drug: Upward titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upward titration of morphine after initial benefit
Trial: 26036212
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen at 0.625 mg/d (n=5279)
Trial: 17650793
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Ginkgo biloba (EGb) given additionally to routine treatment for 2 months.
Trial: 17650793
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (control group).
Trial: 2500070
Drug: PSK (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSK (oral) in addition to mitomycin C and 5-FU for over 3 years
Trial: 5306538
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of cholera vaccine
Trial: 5306538
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of cholera vaccine at an interval of 1 month
Trial: 5306538
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of cholera vaccine
Trial: 22964356
Drug: Adenosine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (1.2 mmol/L)
Trial: 18205730
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group consuming high amounts of six selected vegetables (target of 350 g/day for 65 days)
Trial: 16415629
Drug: Reality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reality therapy program
Trial: 27358210
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg and 140 mg
Trial: 25298573
Drug: Boswellia serrata
RxNorm normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia serrata (125 mg, 2 capsules)
Trial: 22616314
Drug: Fixed ratio
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed ratio of morphine and oxycodone combinations (MOX) at ratios 3:2 in study A and 1:2 in study B
Trial: 22616314
Drug: Fixed ratio
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed ratio of morphine and oxycodone combinations (MOX)
Trial: 22616314
Drug: Morphine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine monotherapy
Trial: 17589281
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral therapy plus sibutramine
Trial: 17589281
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral therapy plus placebo
Trial: 17589281
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (regardless of intervention)
Trial: 17589281
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral therapy plus sibutramine (Caucasian group)
Trial: 17589281
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral therapy plus sibutramine (African American group)
Trial: 11880813
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of power and stretch training (PS)
Trial: 4467872
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate tablets, BP, given before meals
Trial: 4467872
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate tablets, BP, given after meals
Trial: 4467872
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release formulation of ferrous salts
Trial: 4467872
Drug: Liquid iron
RxNorm normalized name: Liquid Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid iron preparation
Trial: 24008808
Drug: Brimonidine-timolol fixed
RxNorm normalized name: brimonidine / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine-timolol fixed combination
Trial: 21498674
Drug: O-FC (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-FC (both doses)
Trial: 15982795
Drug: 0.2% citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% citric acid solution (positive control)
Trial: 12818970
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal treatment with mupirocin
Trial: 10977438
Drug: Oral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cefuroxime axetil
Trial: 8875535
Drug: TPN supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN supplemented with 10 mg of iron as iron dextran daily (group 2)
Trial: 1671884
Drug: Ditiocarb sodium
RxNorm normalized name: Ditiocarb zinc
DrugBank: Ditiocarb (DB02520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ditiocarb sodium (400 mg/m2 orally for 24 weeks)
Trial: 29576447
Drug: Telephone support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone support for breastfeeding (weekly for 2 months, then every 2 weeks until 6 months)
Trial: 20659762
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg aspirin daily for two months
Trial: 20659762
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin daily for two months
Trial: 20659762
Drug: Chronic ASA
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic ASA therapy
Trial: 15855578
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nateglinide
Trial: 15855578
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg nateglinide
Trial: 11923801
Drug: Combined Azimilide
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Azimilide (100 and 125 mg)
Trial: 10615220
Drug: Parsley intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsley intervention (3.73‐4.49 mg apigenin/MJ)
Trial: 7793179
Drug: Succinylcholine 1.0‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0‐1.5 mg kg‐1
Trial: 20109071
Drug: Sorafenib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 100 mg BID
Trial: 20109071
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg BID
Trial: 20109071
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg BID
Trial: 20109071
Drug: Sorafenib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 300 mg continuous
Trial: 20109071
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg continuous
Trial: 18817605
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg.day) for 3 days
Trial: 15311643
Drug: Antibiotic levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic levels drawn from a central venous catheter (CVC)
Trial: 15311643
Drug: Antibiotic levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic levels drawn from a peripheral vein
Trial: 1303482
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg and 10 mg)